RBC Capital Maintains Outperform on Cytokinetics, Raises Price Target to $95

Benzinga · 3d ago
RBC Capital analyst Leonid Timashev maintains Cytokinetics (NASDAQ:CYTK) with a Outperform and raises the price target from $87 to $95.